Skip to content

Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal

Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04906941
Acronym
GADO-QSM
Enrollment
73
Registered
2021-05-28
Start date
2022-01-21
Completion date
2023-07-19
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

White Matter Disease

Brief summary

Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.

Detailed description

Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.

Interventions

DEVICEMRI

SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment. \* Sense 2 \* 2: 9min33s

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients over 18 years old * with an inflammatory CNS pathology * to benefit as part of care from an MRI with injection of gadolinium * consent to participate in the study * beneficiary of a social protection scheme

Exclusion criteria

* pregnant or breastfeeding woman * patient benefiting from a legal protection measure * Patient having performed more than 3 MRI exams with gadolinium injection during his life Secondary

Design outcomes

Primary

MeasureTime frameDescription
mean of the delta observed between the QSM of the white matter before and after injection of gadolinium1 DAYmean of the delta observed between the QSM of the white matter before and after injection of gadolinium

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026